Clinical trials have shown body weight reductions of 15 to 20% in some participants, which explains why these medications have exploded in popularity beyond diabetes treatment (Wilding et al., 2021, New England Journal of Medicine)
To read the full report and explore the patent data, visit: www.i-mak.org/glp-1 About I-MAK The Initiative for Medicines, Access and Knowledge (I-MAK) is a 501(c)(3) organization with a mission to build a more just and equitable medicines system
18 , e1010212 (2022)
Iron metabolism in obesity and metabolic syndrome
Women should contact their GP or specialist if they develop severe or persistent symptoms potentially related to oestrogen changes, including: Significant worsening of menopausal symptoms (hot flushes, night sweats, mood changes) Vaginal dryness or discomfort affecting quality of life Unexplained changes in libido or sexual function Symptoms suggestive of bone health concerns (unexplained fractures, significant height loss) Mood disturbances or depressive symptoms Seek urgent medical attention if you experience: Severe, persistent abdominal pain (especially radiating to the back) with or without vomiting, which could indicate pancreatitis Upper right abdominal pain, fever, or yellowing of the skin/eyes, which might suggest gallbladder disease Signs of dehydration (extreme thirst, dry mouth, reduced urination, dizziness) Suspected pregnancy while taking semaglutide Routine monitoring during semaglutide treatment should follow NICE guidance for diabetes management or weight management programmes
Supplementary Information Supplementary data to this article can be found online at ESM 1 (download DOCX (DOCX 14 kb) Rights and permissions About this article Cite this article Naigaonkar, A., Dadachanji, R., Hinduja, I
